Tag Archives: David Maris

Wells Fargo Reaffirms Their Hold Rating on Mallinckrodt (MNK)

Wells Fargo analyst David Maris maintained a Hold rating on Mallinckrodt (MNK – Research Report) today. The company’s shares closed last Monday at $6.04. According to TipRanks.com, Maris has 0 stars on 0-5 star ranking scale with an average return

Mallinckrodt (MNK) Receives a Hold from Wells Fargo

In a report issued on December 6, David Maris from Wells Fargo maintained a Hold rating on Mallinckrodt (MNK – Research Report). The company’s shares closed last Monday at $3.41, close to its 52-week low of $1.43. According to TipRanks.com,

Wells Fargo Maintains a Buy Rating on Emergent Biosolutions (EBS)

In a report released today, David Maris from Wells Fargo maintained a Buy rating on Emergent Biosolutions (EBS – Research Report). The company’s shares closed last Monday at $56.18. According to TipRanks.com, Maris is ranked 0 out of 5 stars

Wells Fargo Maintains a Hold Rating on Mallinckrodt (MNK)

In a report released today, David Maris from Wells Fargo maintained a Hold rating on Mallinckrodt (MNK – Research Report). The company’s shares closed last Monday at $2.35, close to its 52-week low of $1.43. According to TipRanks.com, Maris has

Wells Fargo Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

Wells Fargo analyst David Maris maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today. The company’s shares closed last Monday at $133.26. According to TipRanks.com, Maris has currently no stars on a ranking scale of 0-5 stars,

Wells Fargo Sticks to Their Buy Rating for Allergan (AGN)

Wells Fargo analyst David Maris maintained a Buy rating on Allergan (AGN – Research Report) today. The company’s shares closed last Monday at $157.87. According to TipRanks.com, Maris has 0 stars on 0-5 star ranking scale with an average return